Pharmacy Market
Businesswire | July 26, 2023
Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials.
According to the FDA and the FD&C Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of sterile water for injection.
“We are proud to be a force for change in the pharmaceutical industry, and we are grateful to the FDA for recognizing the importance of this critical-need product,” said Aman Ahmed, Director of Government Relations and International Sales at Nexus. “The approval of this product is an important step in continuing our efforts to alleviate drug shortages and bring pharmaceutical manufacturing back to the U.S.”
Nexus Pharmaceuticals’ Sterile Water for Injection will be available in cartons of 25 vials.
About Sterile Water for Injection, USP
Sterile Water for Injection, USP is a sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection.
This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.
About Nexus Pharmaceuticals LLC
Nexus Pharmaceuticals LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.
Read More
VIEWS AND ANALYSIS, PHARMACY MARKET
PRNewswire | July 31, 2023
LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023.
Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increase efficiency, and more. Now, its services include proven, worry-free turnkey DSCSA compliance, thanks to LSPedia's easy-to-use, comprehensive OneScan software suite.
Sandy Greco, President of Altro Pharmaceuticals, noted, "Getting DSCSA right is essential to the smooth flow of business in the pharma supply chain, so we take it incredibly seriously, and we absolutely want our customers to succeed with it. LSPedia has the industry's best track record for user experience, scalability, and success – we can say for sure we're offering the best service available."
LSPedia's OneScan Suite enables manufacturers and wholesalers to quickly achieve full compliance with all DSCSA requirements, including serialization, sending and receiving EPCIS data, verification, and interoperability. Further, the solution includes access to LSPedia's Investigator for Exceptions Management, the industry's gold standard for alerting, resolving, and preventing EPCIS transaction errors.
"Altro is a perfect partner for LSPedia," said LSPedia CEO Riya Cao. "With so little time left before the compliance deadline, access and convenience are essential. Altro supports its customers with a deep service portfolio, and there's every reason it should include easy, complete DSCSA compliance."
About LSPedia
LSPedia is a leading provider of turnkey DSCSA compliance and SaaS solutions in the pharmaceutical industry. CMOs, manufacturers, 3PLs, wholesale distributors, dispensers, and healthcare providers use LSPedia's OneScan solution to make, move, track, verify, ship, and receive serialized products at every point in the supply chain.
As the largest processor of serialized data in the industry, LSPedia builds solutions with workflow, automation, and data security at their core. OneScan delivers flexible integrations, high-performance product verification, and state-of-the-art EPCIS data exchange; LSPedia's Investigator platform is the gold standard for serialization exceptions management, as the first collaborative platform to resolve EPCIS errors and supply chain issues in real time.
Read More
Pharmacy Market
Businesswire | June 30, 2023
NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry.
This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal method for scientists utilizing surface plasmon resonance (SPR), who predominantly use biotinylated proteins for affinity screening or binding affinity assays. “Now, direct comparison of binding affinities from an immobilized method to the in-solution, immobilization-free technique of Spectral Shift is possible,” says Regina Borovac, Consumables Product Manager at NanoTemper Technologies. “And, not only that, it enables those who already use Spectral Shift to analyze a broader range of interactions, tackling even more projects involving complex targets.”
Spectral Shift is a growing power in molecular affinity measurements
Because of Spectral Shift’s early success in removing roadblocks for scientists who have found difficulty finding candidates for their complex targets, NanoTemper is continuing to invest in creating products that empower scientists to do more with Spectral Shift technology.
"We’ve put Spectral Shift technology into Dianthus, our affinity screening instrumentation, and Monolith X, our instrumentation for molecular interactions, and they’ve now become a necessity for anyone tackling challenging disease targets,” comments Jocelyn Davé, Chief Product Officer at NanoTemper Technologies. “When it comes to addressing difficult and undruggable targets, there is no other company with the ability to outperform SPR in this category."
About NanoTemper Technologies
Our mission at NanoTemper Technologies is to create biophysical tools for scientists in drug discovery and development who need to tackle challenging characterizations. Working with scientists striving to make a difference in the world gets us excited. If you’re facing challenges with affinity screening, molecular interactions, or protein stability, let’s talk.
Read More